12406 HORESHAM STREET, CARMEL, IN
Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Reports Second Quarter 2026 Financial Results and Corporate Highlights
CEO Departure - Kent P. Hawryluk Steps Down from MBX Biosciences
Investor Presentation
Material disclosure
Reports First Quarter 2026 Financial Results and Corporate Highlights
Annual Report to Security Holders
Q2
Q1
FY 2025
Q3
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
S-1MEF